Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Techno who wrote (686)	3/6/2000 11:14:00 PM
From: Carter Berezay	Read Replies (1) \| Respond to of 792

?? = RBC Dominion Securities Carter B.

To: Techno who wrote (686)	3/8/2000 8:36:00 AM
From: don jackson	Read Replies (1) \| Respond to of 792

Micrologix announces $40 million financing VANCOUVER, March 8 /CNW/ - Micrologix Biotech Inc. is pleased to announce that it has agreed to a $40 million financing with a syndicate of underwriters co-led by TD Securities Inc. and Yorkton Securities Inc. and including RBC Dominion Securities Inc., Goepel McDermid Inc. and Canaccord Capital Corporation. The underwriters have agreed to purchase on a private placement basis, 4,000,000 special warrants at a price of $10.00 per special warrant. Each special warrant will entitle the holder to acquire, at no additional cost, one common share of Micrologix. The completion of the special warrant financing is subject to regulatory approvals and certain other customary conditions and is expected to close on or about March 20, 2000. The proceeds from the financing will be used principally to fund later stage clinical development of MBI 226, Micrologix's lead drug product for the prevention of central venous catheter-related bloodstream infections and to advance other products through clinical trials. In January 2000, MBI 226 successfully completed Phase II; the Company plans to initiate Phase III clinical trials in Q3 2000. These studies will form the basis for a New Drug Application to market MBI 226 in the United States. Proceeds from the financing will also be used to fund Phase II clinical trials of MBI 594AN for the treatment of acne and MBI 853NL for the prevention of Staphylococcus aureus (S. aureus) hospital-acquired infections. Each of these drug products is in Phase I trials in the US with Phase II anticipated to commence in H2 2000. Micrologix Biotech Inc. is a biopharmaceutical company developing novel drugs to treat severe and life-threatening diseases-particularly those caused by antibiotic-resistant microorganisms. Micrologix was granted fast track designation by the US Food and Drug Administration for MBI 226, an antimicrobial drug product for the prevention of central venous catheter-related bloodstream infections which the Company anticipates will be in Phase III clinical trials in Q3 2000. In Q1 2000, Micrologix initiated Phase I clinical trials of MBI 594AN for the treatment of acne and MBI 853NL for the prevention of hospital-acquired S. aureus infections. The Company anticipates completing both trials by mid-2000. Micrologix's portfolio of drug candidates is based on improved analogs of the anti-infective peptide compounds found in the host-defense systems of most life forms.